The human gastrointestinal tract hosts a diverse network of microorganisms, collectively known as the microbiota that plays an important role in health and disease. For instance, the intestinal microbiota can prevent invading microbes from colonizing the gastrointestinal tract, a phenomenon known as colonization resistance. Perturbations to the microbiota, such as antibiotic administration, can alter microbial composition and result in the loss of colonization resistance. Consequently, the host may be rendered susceptible to colonization by a pathogen. This is a particularly relevant concern in the hospital setting, where antibiotic use and antibiotic-resistant pathogen exposure are more frequent. Many nosocomial infections arise from gastrointestinal colonization. Due to their resistance to antibiotics, treatment is often very challenging.
| INTRODUCTION
The intestinal microbiota has important implications in human health and disease. One of its clearest roles has been in providing protection against enteric bacterial pathogens. This is particularly important in the hospital setting to prevent nosocomial (i.e. hospital-acquired) infections originating from the gastrointestinal tract. The patient's commensal microbiota can exclude these pathogens from colonizing the intestinal tract. However, under certain circumstances the patient may develop a compromised microbiota that can no longer protect against colonization by exogenous bacteria. Consequently, these patients can become colonized with a pathogen that can then proliferate to high densities; the gastrointestinal tract can thus serve as an important reservoir for a variety of bacterial pathogens. This poses two important concerns. First, densely colonized patients serve as reservoirs for patient-to-patient transmission, contributing to the endemic persistence of nosocomial infections in hospitals. Second, the pathogen can cause potentially life-threatening disease, especially in immunocompromised patients. Therefore, studying the intestinal microbiota can guide strategies to defend against infectious enteric pathogens, and thereby prevent these complications. Although the microbiota has been implicated in preventing pathogen colonization, the specific contributions and mechanisms that mediate this protection are incompletely defined and continue to be an active area of investigation. This review will explore our current knowledge of the DOI: 10.1111/imr.12563
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The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens Sohn Kim | April Covington | Eric G. Pamer 4 The degradation of these complex carbohydrates yields the release of volatile short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate that are reabsorbed by the host for energy. Additionally, SCFAs have been implicated in regulating intestinal epithelial cell growth, 5 and differentiation and stimulation of the immune system 6 among various other important biological processes.
Although the Bacteroides genus contributes important metabolic functions and generally maintains a beneficial relationship with the host when retained in the intestinal lumen, certain members within this genus can become pathogenic if they disseminate. For instance,
Bacteroides fragilis is typically found in the lower gastro-intestinal tract lumen, and has been shown to have beneficial effects, such as stimulating host immune development. 7 However, it is also the most commonly isolated species from infections caused by an obligate anaerobic pathogen. It commonly causes abdominal abscesses and bloodstream infections if the intestinal mucosa is perforated and subsequently traversed. 8 Most Bacteroides that remain in the intestinal lumen do not cause intestinal disease, with one exception: Enterotoxigenic B. fragilis (ETBF) produces a toxin termed B. fragilis toxin (BFT) that causes colitis and has been associated with promoting colon tumorigenesis. 9, 10 In addition, Bacteroides spp. have the most antibiotic resistance mechanisms, and the highest resistance rates of all obligate anaerobic pathogens. 
| Firmicutes
The Firmicutes phylum is composed of both obligate and facultative anaerobic bacteria. Most members are Gram-positive, and most can form endospores, providing an ecological advantage for survival under adverse conditions. Endospores are dormant, non-reproductive structures that the bacterium can reduce itself to when encountering environmental stress. Endospores can survive in the absence of nutrients and are remarkably resistant to oxygen, ultraviolet radiation, desiccation, extreme temperatures, and chemical disinfectants. This enables bacteria to lie dormant for extended periods of time, and reactivate into its metabolically active state when the environment becomes favorable.
The Clostridia class within this phylum contains a highly heterogeneous group of bacteria that can further be separated into clusters.
Members of Clostridium cluster XIVa and IV represent a majority of the organisms residing in the intestinal tract and have been implicated in a number of beneficial roles. These bacteria are thought to preferentially colonize between mucosal folds to establish a close relationship with the intestinal epithelial cells to help maintain them. 12 Species within these clusters are well known to release butyrate as an end-product of fermentation, which like the SCFAs produced by Bacteroides spp., promote intestinal epithelial health. Additionally, members of these clusters promote host immune homeostasis in the intestine by inducing colonic T regulatory cells. 13 Other clusters of the Clostridia class, however, include important pathogens that cause human disease including members of cluster I, C. perfringens and C. tetani, as well as C. difficile, a member of cluster XI. 
| Actinobacteria
The Actinobacteria phylum is composed of aerobic and anaerobic 
| Proteobacteria
The Proteobacteria phylum encompasses a wide variety of Gramnegative bacteria. 
| Anatomic distribution
The gastrointestinal tract is comprised of the stomach, small intestine, cecum, large intestine, and rectum. There are several changes that occur in the environment along this tract. For instance, the pH and oxygen concentration exist on a gradient beginning in the acidic and aerobic stomach and continuing to the more neutral and anaerobic colon. Additionally, nutrient sources shift as resident microbes digest dietary components. 20 Particularly, most simple sugars are absorbed in the terminal ileum, and therefore most carbohydrate sources beyond the ileocecal valve are host-derived mucins or dietary carbohydrates indigestible by host enzymes. As a result of several factors, bacteria have a specific distribution in the intestine. The total density of bacteria is greater in the colon than the small intestine. Generally, members belonging to Lactobacillales or Proteobacteria are the major residents of the small intestine. However, in the colon bacteria from
Bacteroides and Clostridiales become the dominating members. 21 
| The microbiome
The collective genes that an individual's intestinal microbiota encompasses are known as the microbiome. It overwhelmingly surpasses the coding capacity of the human genome with more than 3 million genes. 22 Although there is large inter-individual variability in the bacterial species comprising the host's microbiota, many microbial genes share functions, resulting in high functional redundancy between microbiomes. These overlapping functions can be considered the core microbiome shared among healthy individuals. 23, 24 
| Antibiotic pharmacokinetics
Pharmacokinetics is the study of how a drug moves into, through, and out of the body. Considering the pharmacokinetics of an antibiotic can be helpful to understand its effects on the intestinal microbiota.
Theoretically, an antibiotic can only alter the composition of the intestinal microbiota by direct exposure, which is only achieved if it reaches the intestinal lumen. While oral administrations are directly delivered to the intestinal lumen, systemic administrations can also indirectly reach the intestine. Systemic antibiotics circulating in the blood eventually reach the liver where they may undergo modifications; then depending upon the antibiotic, they may either be concentrated and excreted into the bile or returned to the blood as waste products for renal clearance.
Importantly, bile is delivered to the gastrointestinal tract and excreted in the feces, while blood is filtered by the kidneys and passed through the genitourinary tract for excretion in the urine. 35 Generally, hydro- Similar patterns of long-term changes to the composition and diversity of the microbiota have been observed with the use of ampicillin and clindamycin. 32, 37 The expanding bacterial populations during early recovery of the microbiota varied across studies and largely depended on the The pharmacological properties of select antibiotics and their effect on the microbiota are shown. Possible routes of administration-not just the methods commonly used in the clinical setting-are described. Various bacterial exceptions are excluded from spectrum; and moderate absorption and high absorption are defined as 40%-60% and 61%-100%, respectively. Antibiotics may be excreted unchanged in the urine, bile, and/or feces. These antibiotics, depending upon route of administration, may also affect the diversity of species in the intestinal microbiota. These changes may be short-term (less than 2 weeks) or long-term (greater than 2 weeks).
a Primary excretion mechanism.
initial commensal bacteria present after discontinuing antibiotic treatment. Generally, expansion of members from the Proteobacteria phylum was common. Furthermore, the length of time that an antibiotic reduced the microbiota diversity correlated with the window of susceptibility to intestinal colonization by various nosocomial pathogens. 29, 32, 33, 37 Upon reaching the intestine, an antibiotic's effect on the compo- Thus, an antibiotic's spectrum of activity and intestinal absorption, in part, determine its impact on the microbiota composition and a host's susceptibility to colonization by pathogens. These can be important aspects, among various other factors, to consider when choosing an antibiotic and predicting its effects on the intestinal microbiota.
| NOSOCOMIAL INFECTIONS OF THE GASTROINTESTINAL TRACT

| Immunocompromised patients are a high-risk population
The microbiota and its role in protecting against infectious diseases is particularly important among hospitalized immunocompromised patients. These individuals with immune suppression, particularly those receiving chemotherapy or undergoing hematopoietic stem cell transplantation, are at an increased risk of infection originating from the gastrointestinal tract. 38, 39 Prophylactic administration of antibiotics can prevent these infections. However, antibiotics can compromise the intestinal microbiota while simultaneously giving rise to antibioticresistant bacteria. There are predominantly two general complications that typically result as a consequence. Colonization with C. difficile can cause intestinal disease, 40 whereas other common nosocomial bacterial pathogens can expand in the gastrointestinal tract and translocate into the bloodstream to cause systemic disease. 41 We will review the pathogenesis of both of these types of infections that can arise from colonizing the gastrointestinal tract.
| Bloodstream infections originating from the gastrointestinal tract
Bloodstream infections originating from the gastrointestinal tract that are encountered in immunocompromised patients can result from changes in the microbiota and damage to the mucosal barrier in the setting of an impaired immune system. This is mediated by the combination of chemotherapy, irradiation, and antibiotics that ultimately enable intestinal bacteria to disseminate systemically. The most common bacteria to translocate are oxygen-tolerant pathobionts including vancomycin-resistant Enterococcus, Enterobacteriaceae such as E. coli
and Klebsiella spp., and viridans streptococci. [41] [42] [43] [44] Cytotoxic chemotherapy remains one of the most common treat- Therefore, the loss of cells from the myelocyte compartment has the greatest downstream impact on the degree of neutrophil deficiency (i.e. neutropenia), and the recovery of cells from this population largely determines the duration of neutropenia. 48 Chemotherapy-induced neutropenia can render the patient susceptible to certain infections.
Therefore, prophylactic broad-spectrum antibiotics are commonly administered to prevent opportunistic infections in the immunocompromised patient.
Due to these changes, immunocompromised patients are specifically susceptible to infections originating from the gastrointestinal tract. First, the patient can develop neutropenia which impairs the patient's ability to limit bacterial invasion. Second, the patient can be administered broad-spectrum antibiotics that can, together with chemotherapy, promote intestinal dysbiosis and expansion of antibiotic-resistant pathogens. Third, the patient can develop mucositis, creating a portal for intestinal bacteria to enter systemic circulation. Under these circumstances, the colonized pathogen can traverse across the epithelium and enter the bloodstream to establish infection. The pathogen can thereby reside in an intestinal reservoir but continuously seed bloodstream infections when host defenses are impaired.
| C. difficile pathogenesis
Clostridium difficile infection in immunocompromised patients, like
HSCT patients, is far more frequent than in the general patient population. [49] [50] [51] [52] [53] [54] A steady increase in the incidence of C. difficile infection has been continuing for decades, partially attributed to the rise in emerging antibiotic-resistant strains. 55, 56 Hosts are rendered susceptible to opportunistic CDI by antibiotic-induced perturbations of the intestinal microbiota that result in the loss of colonization resistance. 57 This poses a concern, particularly in the hospital setting, where C. difficile is easily communicable from patient reservoirs. Although an obligate anaerobe, C. difficile persists in the environment and is readily transmitted from individuals due to its ability to form an endospore. However, despite its proven efficacy, FMT therapy still remains a cumbersome treatment that is not commonly performed. The composition of feces is variable, incompletely defined, and complex. While it contains protective species, it simultaneously carries the potential for risks that cannot be reliably detected by current technology. These risks depend upon the microbiota composition and the recipient's genotype and include the uncertainty of transmitting undetected pathogens and other undefined microbes associated with the development of various disorders including obesity, metabolic syndrome, and autoimmune diseases. 64 Therefore, identifying and comprehensively characterizing the precise bacterial species that mediate colonization resistance can standardize therapeutic input and reduce unpredictable outcomes.
| Key members of the intestinal microbiota mediate colonization resistance
It has been known for over 50 years that commensal anaerobes confer protection against exogenous pathogens. 65 However, the specific bacterial species contributing to colonization resistance against various enteric pathogens are incompletely defined. While it has been argued that the recovery of a complex microbiota is important for reestablishing colonization resistance, 66 a growing number of studies that analyzed the microbiome of antibiotic-treated mice has led to a compelling argument for, and the subsequent identification of, a few key members that are sufficient to protect against specific pathogens, including C. difficile, VRE, and Listeria monocytogenes. [67] [68] [69] These studies demonstrated that in mouse cohorts treated with antibiotics, there is a wide distribution in the degree of susceptibility to intestinal pathogen colonization following partial microbiota recovery.
Comparing mice that are highly susceptible to pathogen colonization with resistant mice revealed that both groups can have a microbiota with equally low diversity, but that the specific bacterial taxa compositions varied. 67, 69 These results indicated that the contributions of specific bacterial species, in the absence of a complex microbiota, are sufficient to restore varying degrees of colonization resistance.
Subsequent correlation analyses between pathogen susceptibility and bacterial taxa abundance can identify species that correlate with protection against a pathogen. This strategy led to the recent identification of a four-member bacterial consortia that, upon colonizing germ-free mice, confer in vivo resistance to Listeria monocytogenes infection. This enabled the researchers to dissect the impact of ARM-derived strains on VRE colonization with minimal interference from a recovering indigenous microbiota. This approach led to the discovery of a four-member bacterial consortium that cooperates to eliminate dense intestinal VRE colonization from mice. 68 Additionally, several studies have demonstrated that a small consortium of commensal bacteria can treat patients colonized with C. difficile. The first of these studies discovered in the late 1980s that 10 commensal bacterial species cured patients with recurrent C. difficile infection. 70 A following study used mice infected with C. difficile to show a consortium of six phylogenetically diverse bacteria can clear C. difficile infection from the intestine, 71 while another study used germ-free mice to show that a single Lachnospiraceae isolate can reduce the severity of C. difficile infection. 72 
| DIRECT MECHANISMS OF COLONIZATION RESISTANCE
| Defining direct colonization resistance
Direct mechanisms of colonization resistance are characterized by the commensal microbiota's ability to restrict exogenous microbial colonization or prevent pathogenic overgrowth of indigenous microbial members strictly through bacterial factors, independent of any interaction with the host (Figure 1 ). and E. coli HS, were capable of utilizing distinct but overlapping sets of defined sugars. 78 Neither of the commensal E. coli strains, on their own, utilized all five of the sugars that EHEC was capable of using. However, the combination of the two commensal E. coli strains utilized all five of these sugars, and thereby completely occupied EHEC's nutrientdefined niche. Mice colonized with only one of the commensal E. coli strains could not resist EHEC colonization. However, co-colonization with both commensal E. coli strains successfully prevented EHEC colonization. 78 This suggests that the distinct but overlapping nutritional profiles of related species in the intestinal microbiota can together saturate a metabolically related pathogen's niche and outcompete its colonization.
| Nutrient depletion
A similar competition for nutrients between a pathogen and the microbiota was demonstrated with host-derived glycans. The mucus layer lining the gastrointestinal tract is primarily composed of mucins, which are heavily O-glycosylated glycoproteins. The O-glycan structures present in mucin are diverse and frequently modified by the sugars fucose and sialic acid. 80 Many commensal and pathogenic bacteria utilize sialic acid as a source of energy, carbon, and nitrogen. 81 However, sialic acid must be cleaved and released from mucin for access. Some commensal bacteria, like Bacteroides thetaiotaomicron express sialidase which liberates the sialic acid residues from mucin, and thereby provides an important nutrient source for the surrounding microbial community. 82, 83 Commensal bacteria can antagonize pathogens by competing for the same niche and acquiring nutrients, like sialic acid, more efficiently. C. difficile growth within the intestine of mice was determined to be, at least in part, dependent upon the concentration of free sialic acid. A complex microbiota colonizing the intestine of mice resulted in low levels of free sialic acid, which suggests that this metabolic niche is already efficiently occupied by the indigenous microbial community. Importantly, antibiotic treatment compromises the microbial community occupying this niche. Antibiotic-treated mice had an elevation of free sialic acid levels within the intestine, which promoted C. difficile expansion. 84 Together, these experiments suggest the intestinal microbiota likely outcompete C. difficile for available sialic acid, resulting in restricted C. difficile growth.
Additionally, studies have demonstrated that C. difficile competes for microbiota-associated metabolites as an important nutrient source in the intestine. The commensal bacterium, B. thetaiotaomircon, is a primary fermenter that produces high levels of succinate as a byproduct in carbohydrate metabolism. There are various secondary fermenters, including C. difficile, that compete for succinate consumption. 85 The reduction of succinate to butyrate can be coupled to the Signaling through the inflammasome results in the downstream production of proinflammatory cytokines including IL-18. IL-18 enhances the production of antimicrobial peptides, including ANG4. Certain commensal bacteria, like Clostridium scindens, can dehydroxylate primary bile acids into secondary bile acids using the enzyme 7α-hydroxysteroid deyhydrogenase, which inhibits the vegetative growth of C. difficile (B). The microbiota also maintains the epithelial barrier by inducing mucus production, and transcriptional activation of the nuclear factor-κB (NF-κB) within epithelial cells to delay apoptosis and repair tissue. Pathogens are restricted at sites of epithelial damage by the epithelial cell's downstream expression of the chemokine CXCL1 that recruits neutrophils, as well as expression of IL-12 that activates ILC1s to release IFNγ for phagocyte recruitment (C). Direct mechanisms of colonization resistance include bacteriocin production, nutrient depletion, and type VI secretion systems (D-F). Several commensal bacteria have been identified to produce bacteriocins with a narrow spectrum of activity that inhibit specific pathogens with minimal impact to the indigenous microbiota (D). Additionally, the microbiota competes with pathogens for various nutrients, including dietary and host-derived carbohydrates, as well as microbial metabolites like succinate, which drives a reduction in pathogen colonization (E). Gram-negative bacteria in the microbiota, like the Bacteroidales order, can deliver toxins to pathogens in a contact-dependent manner via the type VI secretion system. IL, interleukin oxidation of NADH to NAD+, thereby replenishing the pool of avail- 
| Bacteriocin production
Bacteriocins are ribosomally synthesized peptides that are active against other bacteria and against which the producer has a specific immunity mechanism. This encompasses a large, heterogeneous group of peptides that are usually classified into post-translationally modified peptides (class I) and unmodified peptides (class II). Another study screened bacterial strains isolated from resected human terminal ilea, which identified Lactobacillus salivarius strain UCC118 as a probiotic candidate. 94 Further studies revealed this bacterium harbored a megaplasmid that encoded the genes for the class II bacteriocin Abp118 that inhibits L. monocytogenes. 95 Oral administration of L. salivarius strain UCC118 reduced intestinal L. monocytogenes colonization in mice compared to a L. salivarius strain that does not produce bacteriocins. Moreover, this protection was lost when mice had been infected with a strain of L. monocytogenes that heterologously expressed the cognate Abp118 immunity protein, AbpIM. 96 Together, these experiments determined that L. salivarius directly inhibits L. monocytogenes in the intestinal tract by the production of the Abp118 bacteriocin.
Bacteriocins have also been implicated to protect against VRE.
Pediococcus acidilactici MM33 is a commensal bacterium isolated from human stool that produces the class II bacteriocin, pediocin PA-1.
97,98
P. acidilacticii MM33 had an associated trend toward reducing intestinal VRE colonization, but further study is warranted to assess the statistical significance of these observations. 99 A similar study identified
Enterococcus faecalis strain CK135, a research strain derived from the commonly studied OGR1F strain, protected against VRE. The strain harbored a plasmid, pPD1, that encoded the enterococcal bacteriocin, bacteriocin 21 (bac-21). 100 The expression of this bacteriocin conferred a colonization advantage by antagonizing and displacing related indigenous species. E. faecalis CK135 was shown to specifically compete and ultimately reduce VRE colonization in mice. 101 Bacteriocins produced by Gram-negative bacteria are collectively called microcins, despite representing different classes of bacteriocins.
Microcins usually exhibit a narrow spectrum of activity, predominantly against other Gram-negative bacteria. 89 E. coli Nissle 1917 is a wellstudied probiotic that produces two microcins. 102 Both are implicated in limiting Enterobacteriaceae overgrowth during dysbiosis. 103 Some microcins target cells that express the same nutrient receptors, and hijack these transporters to get internalized into the cell where it can exert its inhibitory effect. 104 Specifically, EcN microcins target siderophore receptors expressed by other competing bacteria. 105 Siderophores are synthesized and secreted by certain commensal bacteria and pathogens, and act to retrieve iron, an essential nutrient, from the environment. Eventual reuptake of the iron-bound siderophore occurs through a specific membrane receptor that microcins strategically target. 106 EcN microcins are suggested to have a posttranslationally modified siderophore moiety at the C terminus; this enables them to intercept cells expressing siderophore receptors, and subsequently antagonize them. 102, 104 EcN administration led to the reduced colonization of E. coli or Salmonella enterica in infected mice. 103 
| Type VI secretion system
Type VI secretion systems (T6SSs) have only been identified in Gramnegative bacteria, and most often mediate interactions between
Gram-negative bacterial species that are in close proximity to each other. It involves the contact-dependent transport of proteins from a donor cell to a recipient cell. 107 This system is composed of two main complexes that assemble with additional bridging and cytoplasmic components. The first complex is membrane-associated, and includes the assembly of two proteins that are homologous to other bacterial secretion systems. The second complex is loaded with the effector protein in the cytoplasm and assembles into a needle-like structure resembling the T4 contractile bacteriophage tail. 108, 109 These two complexes organize together and coordinate the delivery of effector proteins across the envelope of the donor cell and through the outer membrane into the periplasmic space of the recipient cell. The effector protein is often an antimicrobial toxin, and commonly used as a contact-dependent mechanism of bacterial antagonism.
110,111
Several enteric pathogens have T6SSs, including Salmonella enterica, 112 C. rodentium, 113 Aeromonas hydrophila, 114 and enteroaggregative E. coli, 115 which suggests that there may be an adaptive role for the system in the intestine. Since Gram-positive organisms are not known to be targeted by T6SSs, the two major Gram-negative phyla in the intestinal microbiota, Bacteroidetes and Proteobacteria, can potentially be involved in T6SSs. A comprehensive bioinformatics analysis of human intestinal Bacteroidales genomes revealed that more than half of these Bacteroidales species encode T6SS genes. 116 These T6SS loci of human intestinal Bacteroidales species segregated into three evolutionarily distinct genetic architectures (GA) designated GA1, GA2, and GA3. GA1 and GA2 T6SS loci were located on conserved integrative conjugative elements (ICE). This readily enabled transfer between strains and explained the finding that GA1 and GA2
T6SSs are present in diverse Bacteroidales species within the human intestinal microbiota. 116 These findings revealed that the microbiota 
| INDIRECT MECHANISMS OF COLONIZATION RESISTANCE
| Defining indirect colonization resistance
Indirect mechanisms of colonization resistance are characterized by the commensal microbiota's dependence upon host-derived factors in order to provide protection against an exogenous pathogen (Figure 1 ).
| Antimicrobial peptide production
The microbiota can stimulate the host innate immune receptors, and can consequently result in the production of host-derived antimicro- The most well-studied example is the antimicrobial protein RegIIIγ.
Germ-free mice reconstituted with an intestinal microbiota demonstrated that the microbiota drives the expression of RegIIIγ. 121 RegIIIγ 129, 130 Subsequent studies revealed that α-defensin expression can be independent of NOD2 when the genetic background of the mouse strain used in experiments is different. 131 Studies with germ-free mice also suggest that α-defensin expression may be independent of microbial signals. The consequent induction of IL-18 leads to the production of antimicrobial peptides, including ANG4. Moreover, the microbiota produces metabolites that modulate the NLRP6 inflammasome and subsequent antimicrobial peptide expression. For instance, taurine is a bile acid conjugate produced by certain members of the microbiota that has been shown to activate NLRP6 inflammasome signaling and specifically enhance ANG4 production. 133 
| Epithelial barrier maintenance
Mucus covers and protects the intestinal epithelium by maintaining the spatial separation between lumenal bacterial colonization and the host epithelial barrier. 134 The thickness of the mucus is dependent upon the microbiota. Germ-free mice have thinner mucus layers that can grow to the thickness of conventionally raised mice by the administration of microbial products like lipopolysaccharide or peptidoglycan. 135 However, upon mucosal adherence, pathogens like C. difficile repair. 137, 138 The microbiota engages innate immune receptors that can lead to the activation of NF-κB transcription in intestinal epithelial cells, and thereby maintain the integrity of the epithelial barrier. 139, 140 NF-κB leads to the downstream production of proinflammatory cytokines and induces anti-apoptotic factors, stimulates proliferation, and stabilizes tight junctions. 137 
| Bile acid metabolism
In addition to interacting with the host's innate immune system, the microbiota interacts with host-derived molecules, like bile acids, to convert them into toxic products that inhibit C. difficile growth. Bile Additionally, sequestering bile acids by the addition of cholestyramine eliminates C. scinden's inhibitory effect on C. difficile growth. 67 Together, these experiments suggest the commensal bacterium, C. scindens, mediates C. difficile inhibition through the conversion of host-derived primary bile acids into secondary bile acids.
| CONCLUSION
Recent studies have provided insight into the mechanisms mediating colonization resistance against pathogens. However, research in this field is still in an early phase. Considerable research efforts are still in the screening phase to identify important protective species from the microbiota. These recent advances in identifying small consortia of protective microbial members are promising, and establish a catalogue of important species implicated in human health. However, while this simplifies the complexity of the microbiota to a minimum, our understanding of colonization resistance remains incomplete. The recently discovered four-member consortium that can decolonize VRE from the gastrointestinal tract serves as an example. Although the consortium demonstrates impressive efficacy in eradicating VRE colonization, it operates through an undefined mechanism of bacterial cooperation. The future direction of research is in exploring these dynamic relationships between bacteria within the microbiota; dissecting these complex interactive networks will help to isolate the precise mechanisms mediating colonization resistance and provide insight into the foundations that govern specific bacterial interdependencies.
Subsequently, strategies targeted to enhance these mechanisms can provide an alternative to the use of current antibiotics in treating challenging infections. This is particularly relevant to addressing the rise of antibiotic-resistant infections. VRE and several Enterobacteriaceae species are major causes of intestinal nosocomial infection that exhibit concerning degrees of AR. Patients rendered susceptible to intestinal infections because of the loss of microbiota-mediated colonization resistance can harbor high concentrations of these pathogens and contribute to their persistence and transmission. However, the recent discoveries of specific bacteria capable of defending against certain pathogens suggest that reestablishing precise, key components of the microbiota has promising therapeutic potential. A more comprehensive understanding of the microbiota's mechanisms of colonization resistance can guide future strategies for identifying susceptible patients, as well as preventing and treating infections originating from the gastrointestinal tract.
